Has Jamila Benmoussa, MD received payments from drug or device companies?

Yes. Drug and device makers reported $6,104 in general payments to Jamila Benmoussa, MD across 170 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jamila Benmoussa, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jamila Benmoussa, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jamila Benmoussa, MD

Internal Medicine · Albany, NYNPI 1083054332

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,827 of the $6,104 with a category attached, or 62.7%. 27 manufacturers reported payments, led by Medtronic at 33.5% of the total. Reporting peaked in 2019 at $3,277 and has fallen 94.2% since, to $192 in 2025. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,104in general payments, 2019–2025

Across 170 payments — averaging $35.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$2K
Novo Nordisk$1K
Insulet Corporation$389
AstraZeneca$365
Amgen$298
Dexcom, Inc.$200
plus $1K from 21 others

What the payments were for

Consulting fees$87014%
Travel & lodging$1,40723%
Food & beverage$3,82763%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	17	$2,042
Novo Nordisk	33	$1,448
Insulet Corporation	30	$389
AstraZeneca	9	$365
Amgen(2 entities)	10	$298
Dexcom, Inc.	6	$200
Sequel Med Tech, LLC	2	$192
Lilly USA, LLC	16	$149
Tandem Diabetes Care, Inc.	2	$132
Xeris Pharmaceuticals, Inc.	1	$123
Sanofi-aventis U.S. LLC	7	$119
Corcept Therapeutics	2	$98
Johnson & Johnson	7	$98
Mannkind Corporation	5	$70
Merck	4	$62
Antares Pharma, Inc.	3	$51
Abbott	2	$44
Boehringer Ingelheim	2	$35
AbbVie	1	$34
Radius Health, Inc.	2	$32
IBSA Pharma Inc.	2	$27
Shire North American Group Inc	2	$24
Lifescan, Inc.	1	$16
Alfasigma USA, Inc.	1	$16
Eisai Inc.	1	$16
Pfizer	1	$13
Ultragenyx Pharmaceutical Inc.	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Minimed 670G System$1,543
MINIMED 780G$266
TWIIST$150
Ozempic$139
RECORLEV$123
EVENITY$123
FARXIGA$122
t:slim X2 Insulin Pump with Control-IQ$107

How this compares

$6,104 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York →

Medicare billing

Part B allowed, 2024

$71,201

Medicare patients

253

Services billed

767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	15	$1,620
Nano 2nd Gen Pen NeedlePen Needle, Diabetic	11	$619

Paid to pharmacies, not to this prescriber.

Other internal medicine in Albany

Scott BeegleAlbany$1.9M
David DoveEast Hampton$12.3M
Bruce BergerBrooklyn$3.4M
Nicholas RobinsonBuffalo$2.9M
Stephen SaletanNew York$2.6M
Ziad AliNew York$2M
Anthony MartinezBuffalo$1.6M
Javier MoralesGreenvale$1.3M
Ricky HsuNew York$1M
James UnderbergNew York$953K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →